C-13-60 / Chongqing Precision Biotech - LARVOL DELTA

Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial. (ASCO 2025) - "Clinical Trial Registration Number: - The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

CAR T-Cell Therapy • Clinical • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

CAR-T Therapy Targeting CEA in Advanced CEA-Positive Lung Cancer (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Lung Cancer • Oncology • Solid Tumor

CAR-T Therapy Targeting CEA in Advanced CEA-Positive Lung Cancer (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd

IO biomarker • New P1 trial • Lung Cancer • Oncology • Solid Tumor

PBC039: A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=43 | Completed | Sponsor: Weijia Fang, MD | Active, not recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Jun 2024

IO biomarker • Trial completion • Trial completion date • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Study of CEA Targeting CAR-T in the Treatment of CEA-Positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Weijia Fang, MD | N=72 ➔ 50

Enrollment change • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

PBC039: A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: Weijia Fang, MD | Recruiting ➔ Active, not recruiting | Trial completion date: May 2025 ➔ Dec 2025

Enrollment closed • IO biomarker • Trial completion date • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CEACAM5

Study of CEA Targeting CAR-T in the Treatment of CEA-Positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Weijia Fang, MD

New P1 trial • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CEACAM5

A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd

IO biomarker • New P1 trial • Lung Cancer • Oncology • Solid Tumor

Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion. (ASCO 2024) - P1 | "The CEA CAR-T cell therapy had acceptable toxicity via I.P. or I.V. infusion. We have observed a promising antitumor potential by I.P. infusion and a prolonged tumor remission in high-dose group. Further investigation is needed to highlight these findings and the corresponding mechanisms."

CAR T-Cell Therapy • Clinical • P1 data • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Immunology • Lung Cancer • Mucositis • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study. (PubMed, Cytotherapy) - "Taken together, our data suggest that i.p. administration of CAR T cells may be a robust delivery route for effective treatment of cancer."

CAR T-Cell Therapy • Journal • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Hematological Disorders • Hematological Malignancies • Hepatology • Oncology • Pancreatic Cancer • Peritoneal Cancer • Solid Tumor • CEACAM5 • PSCA

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Sep 2024 ➔ Sep 2025 | Trial primary completion date: Sep 2023 ➔ Sep 2024

IO biomarker • Metastases • Trial completion date • Trial primary completion date • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • CEACAM5

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd

Metastases • New P1 trial • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Oncology • Pancreatic Cancer • Rectal Cancer • Solid Tumor

Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors. (PubMed, Cancer Res) - "Furthermore, 5H1P-CEA CAR-T cells exhibited decreased T cell exhaustion and improved T cell phenotype in vivo. In patient-derived xenograft models, hypoxia-responsive CAR-T cells induced more durable antitumor activity than their conventional counterparts. Overall, this study provides an approach to limit CAR expression to the hypoxic tumor microenvironment that could help to enhance CAR-T cell efficacy and safety in solid tumors."

CAR T-Cell Therapy • IO biomarker • Journal • Oncology • Solid Tumor

Precision Biotechnology’s two CAR-T cell drugs have received IND acceptance [Google translation] (pharnexcloud.com) - "...Chongqing Precision Biotechnology Co., Ltd. (hereinafter referred to as 'Precision Biotechnology') has obtained IND applications for 'C-13-60 Cell Preparation' and 'MC-1-50 Cell Preparation' accepted."

New trial • Hematological Malignancies • Oncology • Solid Tumor

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd

CAR T-Cell Therapy • Metastases • New P1 trial • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • ALK • BRAF • NTRK • PD-L1 • ROS1

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd

Metastases • New P1 trial • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CD70 • IL6

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd

Metastases • New P1/2 trial • Breast Cancer • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Oncology • Pancreatic Cancer • Rectal Cancer • Solid Tumor

Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd | Trial completion date: Apr 2023 ➔ Apr 2024 | Trial primary completion date: Jan 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Liver Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • IL6

Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd

New P1/2 trial • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Rectal Cancer • Solid Tumor

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Chongqing Precision Biotech Co., Ltd

IO biomarker • New P1 trial • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Weijia Fang, MD

IO biomarker • New P1 trial • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer (clinicaltrials.gov) - P1/2; N=40; Recruiting; Sponsor: Chongqing Precision Biotech Co., Ltd

Clinical • IO Biomarker • New P1/2 trial • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Thoracic Cancer